Latest Investor Relations News

Transurban Group reveals modest investor uptake in its latest Distribution Reinvestment Plan, with new securities priced at $13.89 and set for issuance in February.

Amcor has reported robust second quarter and half-year results for fiscal 2026, driven by the Berry acquisition and operational synergies. The company reaffirmed its full-year guidance and declared a higher quarterly dividend.

Taiton Resources has completed a significant placement of nearly 12 million shares to Singapore’s GEMS Strategic Resource Fund, bolstering its capital position and signalling confidence from a reputable international investor.

TradeWindow has launched a NZ$1 million Share Purchase Plan to accelerate its Freight AI operating system development and support growth across Australasia. This follows a successful NZ$5.7 million placement, signalling strong investor confidence in the company’s tech-driven future.

Australian Critical Minerals has made significant strides in preparing its flagship Flint Gold-Silver Project for drilling, while strengthening its leadership team and securing fresh capital to fuel exploration.

Qualitas Real Estate Income Fund has concluded its recent rights issue without issuing any shortfall units, a move it says benefits unitholders. The decision finalises the capital raising process initiated in November 2025.

G50 Corp has initiated core drilling at its Golconda Project amid a sharp rise in gallium, gold, and silver prices, while preparing to drill at White Caps. The company’s upgrade to OTCQX aims to boost U.S. investor access, complemented by recent board changes.

Unith Ltd reports a 17% rise in quarterly cash receipts alongside strategic funding and new technology launches, signalling momentum in its AI-driven digital human platform.

CONNEQT Health Limited reported a strong quarter with over 200% sales growth for its CONNEQT Pulse product and completed a $3.1 million institutional placement, while operational cost reductions support a leaner business model.

Horizon Gold appoints mining veteran Scott Williamson as CEO and Managing Director, signaling a strategic leadership shift to accelerate development of its Gum Creek Gold Project.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.